// App-Quantinova.ai

TPS2597 : AMC 095 (AIDS Malignancy Consortium): A phase I study of ipilimumab (IPI) and nivolumab (NIVO) in advanced HIV associated solid tumors (ST) with expansion cohorts in HIV associated solid tumors and classical Hodgkin lymphoma (cHL).

Researchers

Presenter

  • Lakshmi Rajdev

Principal Investigators

  • Elizabeth Y. Chiao

  • Shelly Lensing

  • Richard F. Little

  • Dirk Dittmer

  • Mark H. Einstein

  • Missak Haigentz

  • Joseph A. Sparano

  • Ronald T. Mitsuyasu

Medical Centers

  • Montefiore Medical Center, Bronx, NY

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • University of Arkansas for Medical Sciences, Little Rock, AR

  • Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD

  • Center for AIDS Research (CfAR) Carolina Center for Genome Sciences, Chapel Hill, NC

  • Albert Einstein College of Medicine, White Plains, NY

  • Atlantic Health System, Morristown Medical Center, Morristown, NJ

  • University of California, Los Angeles, Los Angeles, CA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • N/A

Biomarkers

  • Programmed cell death protein 1

  • Cluster of differentiation 8A

  • Cytotoxic T-lymphocyte-associated protein 4

Drug/Treatment

  • Ipilimumab

  • Nivolumab

Outcome

  • N/A

Study Design

  • Multinational

  • Multicenteric

  • Cohort

Phase

  • NA

Study Id's

  • NCT02408861

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved